Truist lifts target to USD 260.00 for Quest Diagnostics stock

Published on 10/15/2026 at 18:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Quest Diagnostics reports third-quarter results on October 22, 2026. Quest Diagnostics stock costs EUR 211.45 on October 15, 2026 at 6:31 p.m. CEST.

Analyst view and reporting date

Truist raised its Quest Diagnostics target to USD 260.00 on September 21, 2026.
Quest Diagnostics will publish third-quarter 2026 results on October 22, 2026.
Quest Diagnostics stock traded at EUR 211.45 at 6:31 p.m. CEST at Lang & Schwarz on October 15, 2026.
Quest Diagnostics had a market capitalization of USD 26.2 billion and a price-to-earnings ratio of 25.17.

Architektur-Render eines modernen unbeschrifteten Labor-Gebäudes bei Dämmerung — Quest Diagnostics US74834L1008 illustriert modernes unbeschriftetes Laborgebäude als Architektur-Render bei Dämmerung mit warmem Innenlicht, Illustration mit AI erstellt.

Truist Financial raised its Quest Diagnostics target to USD 260.00 and kept a Hold rating in a research note dated September 21, 2026, according to MarketBeat. Against the USD 237.13 home-market price at 12:34 p.m. ET on October 15, 2026, that target lies 9.64 percent higher. Quest Diagnostics stock was trading at EUR 211.45 at Lang & Schwarz on October 15, 2026 at 6:31 p.m. CEST.

Results date brings the next test

Quest Diagnostics is scheduled to release third-quarter 2026 results before the U.S. market opens on October 22, 2026. The company will hold its earnings call at 8:30 a.m. ET, according to Morningstar, which carried the company announcement dated September 22, 2026.

Second-quarter figures set the benchmark

In the second quarter of 2026, Quest Diagnostics reported revenue of USD 3.04 billion, up 10.20 percent from the year-earlier quarter. Adjusted earnings per share reached USD 3.12, compared with a USD 2.82 consensus estimate, according to MarketBeat. The company also set fiscal-year 2026 adjusted earnings-per-share guidance at USD 11.05 to USD 11.25.

Valuation and peer comparison

Quest Diagnostics had a market capitalization of USD 26.2 billion, a price-to-earnings ratio of 25.17 and a dividend yield of 1.00 percent on October 15, 2026. The finance data also placed the stock between a 52-week low of USD 164.65 and a high of USD 248.84.

Comparison with peers
Quest Diagnostics (NYSE, USD): P/E 25.17, market capitalization USD 26.2 billion
Labcorp (NYSE, USD): plus 1.55 percent, P/E 26.66, market capitalization USD 26.1 billion
Sonic Healthcare (ASX, AUD): plus 0.65 percent, P/E 15.03, market capitalization AUD 9.1 billion

Price after the Xetra close

The euro quotation was EUR 211.45 at Lang & Schwarz on October 15, 2026 at 6:31 p.m. CEST. The primary listing is on the NYSE, where Quest Diagnostics was last quoted at USD 237.13 at 12:34 p.m. ET on the same date. The next scheduled company event is the October 22, 2026 results release. The further course of trading is shown by the continuously updated real-time quote of Quest Diagnostics stock.